Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -1.88 | 0.09 | -0.00 |
| FCF Yield | -83.54% | -23.14% | -16.11% | -6.96% |
| EV / EBITDA | -0.99 | -2.86 | -2.09 | -6.97 |
| Quality | ||||
| ROIC | -53.90% | -20.51% | -23.95% | -8.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.82 | 0.82 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -100.14% | -22.01% | -96.18% | -141.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | 0.74 | 3.05 | 6.24 |
| Interest Coverage | -28.03 | -105.23 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -32.27 |